7-Alkoxy-4-phenylamino-3-quinolinecarbonitriles as Dual Inhibitors of Src and Abl Kinases

Journal of Medicinal Chemistry

Volumn 47, Issue 7, 2004, Pages 1599-1601

  Boschelli, Diane H ^a   Wang, Yanong D ^a   Johnson, Steve ^a   Wu, Biqi ^a   Ye, Fei ^a   Barrios Sosa, Ana Carolina ^a   Golas, Jennifer M ^a   Boschelli, Frank ^a  

^a WYETH RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2,4 DICHLORO 5 METHOXYPHENYL)AMINO] 3 QUINOLINECARBONITRILE; 4 PHENYLAMINOQUINOLINECARBONITRILE; ABELSON KINASE INHIBITOR; BOSUTINIB; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CHLORINATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; HUMANS; NITRILES; PROTEIN-TYROSINE KINASES; QUINOLINES; SRC-FAMILY KINASES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 1642339546     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0499458     Document Type: Article

References (34)

1. Frame, M. C. Src in Cancer: Deregulation and Consequences for Cell Behavior. Biochim. Biophys. Acta 2002, 1602, 114-130.
2. Irby, R. B.; Yeatman, T. J. Role of Src Expression and Activation in Human Cancer. Oncogene 2000, 19, 5636-5642.
3. Martin, G. S. The Hunting of the Src. Nature Rev. Mol. Cell Biol. 2001, 2, 467-475.
4. Summy, J. M.; Gallick, G. E. Src Family Kinases in Tumor Progression and Metastasis. Cancer Metastasis Rev. 2003, 22, 337-358.
5. Susa, M.; Missbach, M.; Green, J. Src Inhibitors: Drugs for the Treatment of Osteoporosis, Cancer or Both? Trends Pharmacol. Sci. 2000, 21, 489-495.
6. Courtneidge, S. A. Role of Src in Signal Transduction Pathways. Biochem. Soc. Trans. 2002, 30, 11-17.
7. Golas, J. M.; Arndt, K.; Etienne, C.; Lucas, J.; Nardin, D.; Gibbons, J. ; Frost, P.; Ye, F.; Boschelli, D. H.; Boschelli, F. SKI-606, a 4-Anilino-3-quinolinecarbonitrile Dual Inhibitor of Src and Abl Kinases, is a Potent Antiproliferative Agent against Chronic Myelogenous Leukemia Cells in Culture and Causes Regression of K562 Xenografts in Nude Mice. Cancer Res. 2003, 63, 375-381.
8. Capdeville, R.; Buchdunger, E.; Zimmermann, J.; Matter, A. Glivec (STI571, Imatinib), a Rationally Developed, Targeted Anticancer Drug. Nature Rev. Drug Dis. 2002, 1, 493-502.
9. Druker, B. J.; Lydon, N. B. Lessons Learned from the Development of an Abl Tyrosine Kinase Inhibitor for Chronic Myelogenous Leukemia. J. Clin. Invest. 2000, 105, 3-7.
10. Dorsey, J. F.; Jove, R.; Kraker, A. J.; Wu, J. The Pyrido [2,3-d]pyrimidine Derivative PD180970 Inhibits p210Bcr-Abl Tyrosine Kinase and Induces Apoptosis of K562 Leukemic Cells. Cancer Res. 2000, 60, 3127-3131.
11. Wisniewski, D.; Lambek, C. L.; Liu, C.; Strife, A.; Veach, D. R.; Nagar, B.; Young, M. A.; Schindler, T.; Bornmann, W. G.; Bertino, J. R.; Kuriyan, J.; Clarkson, B. Characterization of Potent Inhibitors of the Bcr-Abl and the c-Kit Receptor Tyrosine Kinases. Cancer Res. 2002, 62, 4244-4255.
12. Nimmanapalli, R.; O'Bryan, E.; Huang, M.; Bali, P.; Burnette, P. K.; Loughran, T.; Tepperberg, J.; Jove, R.; Bhalla, K. Molecular Characterization and Sensitivity of STI-571 (Imatinib Mesylate, Gleevec)-Resistant, bcr-abl-Positive, Human Acute Leukemia Cells to SRC Kinase Inhibitor PD180970 and 17-Allylamino-17-demethoxygeldanamycin. Cancer Res. 2002, 62, 5761-5769.
13. Warmuth, M.; Simon, N.; Mitina, O.; Mathes, R.; Fabbro, D.; Manley, P. W.; Buchdunger, E.; Forster, K.; Moarefi, I.; Hallek, M. Dual-specific Src and Abl Kinase Inhibitors, PP1 and CGP76030, Inhibit Growth and Survival of Cells Expressing Imatinib Mesylate-Resistant Bcr-Abl Kinases. Blood 2003, 101, 664-672.
14. Metcalf, C., III; Wang, Y.; Shakespeare, W.; Sundaramoorthi, R.; Keenan, T.; Dalgarno, D.; Bohacek, R.; Burns, K.; Roses, J.; van Schravendijk, M. R.; Ram, M.; Keats, J.; Liou, S.; Adams, S.; Snodgrass, J.; Rivera, V.; Weigle, M.; Iuliucci, J.; Clackson, T.; Frame, M.; Brunton, V.; Sawyer, T. Structure-based Methods to Design Potent and Selective Src/Abl Dual Inhibitors and their Development as Antitumor and Antimetastatic Agents. Proceedings of the 226th American Chemical Society National Meeting; New York, Sept 7-11, 2003; American Chemical Society: Washington, D.C., 2003; COMP-079.
15. Nagar, B.; Bornmann, W. G.; Pellicena, P.; Schindler, T.; Veach, D. R.; Miller, W. T.; Clarkson, B.; Kuriyan, J. Crystal Structures of the Kinase Domain of c-Abl in Complex with the Small Molecule Inhibitors PD173955 and Imatinib (STI-571). Cancer Res. 2002, 62, 4236-4243
16. Boschelli, D. H.; Ye, F.; Wang, Y. D.; Dutia, M.; Johnson, S. L.; Wu, B. ; Miller, K.; Powell, D. W.; Yaczko, D.; Young, M.; Tischler, M.; Arndt, K.; Discafani, C.; Etienne, C.; Gibbons, J.; Grod, J.; Lucas, J.; Weber, J. M.; Boschelli, F. Optimization of 4-Phenylamino-3-quinolinecarbonitriles as Potent Inhibitors of Src Kinase Activity. J. Med. Chem. 2001, 44, 3965-3977.
17. Boschelli, D. H.; Ye, F.; Wu, B.; Wang, Y. D.; Barrios Sosa, A. C.; Yaczko, D.; Powell, D.; Golas, J. M.; Lucas, J.; Boschelli, F. Investigation of the Effect of Varying the 4-Anilino and 7-Alkoxy Groups of 3-Quinolinecarbonitriles on the Inhibition of Src Kinase Activity. Bioorg. Med. Chem. Lett. 2003, 13, 3797-3800.
18. Ziegler, C. B., Jr.; Curran, W. V.; Kuck, N. A.; Harris, S. M.; Lin, Y. I. Synthesis and Antibacterial Activity of some 7-Substituted 1-Ethyl-6-fluoro-1,4-dihydro-4-oxoquinoline-3-carboxylic Acids: Ethers, Secondary Amines and Sulfides as C7 Substituents. J. Heterocycl. Chem. 1989, 26, 1141-1145.
19. Nishimura, Y.; Minamida, A.; Matsumoto, J. A Intramolecular Cyclization of 7-Substituted 6-Fluoro-1,8-naphthyridine and -quinoline Derivatives. J. Heterocycl. Chem. 1988, 25, 479-485.
20. Hennequin, L. F.; Thomas, A. P.; Johnstone, C.; Stokes, E. S. E.; Ple, P. A. Lohmann, J.-J. M.; Ogilvie, D. J.; Dukes, M.; Wedge, S. R.; Curwen, J. O.; Kendrew, J.; Lambert-van der Brempt, C. Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors. J. Med. Chem. 1999, 42, 5369-5389.
21. Smaill, J. B.; Rewcastle, G. W.; Bridges, A. J.; Zhou, H.; Showalter, H. D. H.; Fry, D. W.; Nelson, J. M.; Sherwood, V.; Elliott, W. L.; Vincent, P. W.; DeJohn, D. E.; Loo, J. A.; Greis, K. D.; Chan, O. H.; Reyner, E. L.; Lipka, E.; Denny, W. A. Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions. J. Med. Chem. 2000, 43, 1380-1397.
22. The enzyme data reported here is from a LANCE format assay that differs from the ELISA assay used in our earlier publications (refs 16, 17). Full details for this and the Abl enzyme assay can be found in the Supporting Information.
23. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R. R.; Rao, P. N.; Sawyers, C. L. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification. Science 2001, 293, 876-880.
24. Corbin, A. S.; Buchdunger, E.; Pascal, F.; Druker, B. J. Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571. J. Biol. Chem. 2002, 277, 32214-32219.
25. Nimmanapalli, R.; Bhalla, K. Mechanisms of Resistance to Imatinib Mesylate in Bcr-Abl-Positive Leukemias. Curr. Opin. Oncolol. 2002, 14, 616-620.
26. Shannon, K. M. Resistance in the Land of Molecular Cancer Therapeutics. Cancer Cell 2002, 2, 99-102.
27. La Rosee, P.; Corbin, A. S.; Stoffregen, E. P.; Deininger, M. W.; Druker, B. J. Activity of the Bcr-Abl Kinase Inhibitor PD180970 Against Clinically Relevant Bcr-Abl Isoforms that Cause Resistance to Imatinib Mesylate (Gleevec, STI571). Cancer Res. 2002, 62, 7149-7153.
28. Huron, D. R.; Gorre, M. E.; Kraker, A. J.; Sawyers, C. L.; Rosen, N.; Moasser, M. M. A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-Driven K562 Cells and is Effective Against STI571-resistant Bcr-abl Mutants. Clin. Cancer Res. 2003, 9, 1267-1273.
29. Von-Bubanoff, N.; Veach, D. R.; Miller, W. T.; Li, W.; Sanger, J.; Peschel, C.; Bornmann, W. G.; Clarkson, B.; Duyster, J. Inhibition of Wild-Type and Mutant Bcr-Abl by Pyrido-Pyrimidine Small Molecule Kinase Inhibitors. Cancer Res. 2003, 63, 6395-6404.
30. O'Hare, T.; Stoffregen, E. P.; Abdullah, O. M.; Deininger, M. W.; Rivera, V. M.; Tang, H.; Keats, J.; Metcalf, C., III; Wang, Y.; Sundaramoorthi, R.; Shakespeare, W.; Dalgarno, D. C.; Sawyer, T.; Druker, B. J. Potent Inhibition of Imatinib-Resistant Variants of Bcr-Abl by a Novel Dual Selective Src/Abl Kinase Inhibitor AP23464: Implications for CML Therapy. Blood 2003, 102 (111), Abstract 59.
31. Warmuth, M.; Damoiseaux, R.; Liu, Y.; Fabbro, D.; Gray, N. Src Family Kinases: Potential Targets for the Treatment of Human Cancer and Leukemia. Curr. Pharm. Des. 2003, 9, 2043-2059.
32. Roginskaya, V.; Zuo, S.; Caudell, E.; Nambudiri, G.; Kraker, A. J.; Corey, S. J. Therapeutic Targeting of Src-kinase Lyn in Myeloid Leukemic Cell Growth. Leukemia 1999, 13, 855-861.
33. Warmuth, M.; Bergmann, M.; Priess, A.; Hauslmann, K.; Emmerich, B.; Hallek, M. The Src Family Kinase Hck Interacts with Bcr-Abl by a Kinase-Independent Mechanism and Phosphorylates the Grb2-Binding Site of Bcr. J. Biol. Chem. 1997, 272, 33260-33270.
34. Lionberger, J. M.; Wilson, M. B.; Smithgall, T. E. Transformation of Myeloid Leukemia Cells to Cytokine Independence by Bcr-Abl is Suppressed by Kinase-Defective Hck. J. Biol. Chem. 2000, 275, 18581-18585.